Physician profile
Christopher Mcgrath
NPI 1811316672
$548.25
in general payments reported to CMS, 2019-2025
11 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $56.42 · 2021: $41.50 · 2022: $54.47 · 2023: $228 · 2024: $40.91 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $395.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $199.21 | 2021-2025 | Nucala, Trelegy Ellipta |
| Olympus Corporation of The Americas | $56.42 | 2020 | |
| Abbott Laboratories | $52.28 | 2023-2024 | Proclaim |
| Astrazeneca Pharmaceuticals Lp | $47.97 | 2023-2024 | Breztri, Airsupra |
| Genzyme Corporation | $40.43 | 2023-2024 | |
| Nalu Medical, INC. | $30.42 | 2025 | Nalu Neurostimulation System |
| Averitas Pharma INC. | $28.44 | 2025 | Qutenza |
| Alexion Pharmaceuticals, INC. | $26.87 | 2023 | |
| Amgen INC. | $25.56 | 2023 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.08 | 2023 | Ofev |
| Philips North America LLC | $15.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mcgrath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.